MIRIKIZUMAB - A NEW OPTION IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASES

被引：0

作者：

Olszewski, Jakub ^{[1
]}

Kozon, Katarzyna ^{[1
]}

Sitnik, Magdalena ^{[1
]}

Herjan, Katarzyna ^{[2
]}

Mikolap, Karolina ^{[3
]}

Gastol, Bartlomiej ^{[4
]}

Bara, Maciej ^{[5
]}

Armanski, Piotr ^{[6
]}

Sawczuk, Marcin ^{[7
]}

机构：

[1] Masovian Brodnowski Hosp, PL-03242 Warsaw, Poland

[2] Prof W Orlowski Mem Hosp, PL-00401 Warsaw, Poland

[3] Wolski Hosp Warsaw, PL-01211 Warsaw, Poland

[4] Masovian Specialist Hosp Ostroleka, PL-07410 Ostroleka, Poland

[5] Med Univ Warsaw, Infant Jesus Clin Hosp, PL-02005 Warsaw, Poland

[6] Dist Hosp Sochaczew, PL-96500 Sochaczew, Poland

[7] Med Univ Gdansk, Clin Ctr, PL-80952 Gdansk, Poland

来源：

PROSPECTS IN PHARMACEUTICAL SCIENCES | 2024年 / 22卷 / 03期

关键词：

mirikizumab; IL-23; ulcerative colitis; ULCERATIVE-COLITIS; MAINTENANCE THERAPY; INTERLEUKIN-23; DIAGNOSIS; INDUCTION;

D O I：

10.56782/pps.262

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Mirikizumab is a humanized monoclonal antibody targeting the p19 subunit of interleukin IL-23. Over the past few years, it has been the subject of clinical trials as a potential new treatment for inflammatory bowel diseases, including ulcerative colitis and Crohn's disease. Additionally, mirikizumab has been investigated in clinical trials as a potential treatment for plaque psoriasis. The results of clinical trials for mirikizumab in treating ulcerative colitis led to its approval in the European Union, the United States, Canada, and Japan for treating adult patients with moderately to severely active ulcerative colitis. Despite promising clinical trial results, mirikizumab has not yet been approved for the treatment of Crohn's disease. This review focuses on summarizing the findings from clinical trials of mirikizumab in the treatment of inflammatory bowel diseases. Information is sourced from scientific papers available on PubMed, by searching for "mirikizumab" and "IL-23" and published to March 2024, as well as from published results of clinical trials concerning mirikizumab.

引用

页码：178 / 185

页数：8

共 50 条

[21] Nanotechnology in the treatment of inflammatory bowel diseases
Viscido, Angelo
Capannolo, Annalisa
Latella, Giovanni
Caprilli, Renzo
Frieri, Giuseppe
JOURNAL OF CROHNS & COLITIS, 2014, 8 (09): : 903 - 918
[22] Medical treatment of inflammatory bowel diseases
Van Assche, G
Vermeire, S
Rutgeerts, P
CURRENT OPINION IN GASTROENTEROLOGY, 2005, 21 (04) : 443 - 447
[23] Treatment Strategies in Inflammatory Bowel Diseases
Stallmach, Andreas
Atreya, Raja
Grunert, Philip Christian
Stallhofer, Johannes
de Laffolie, Jan
Schmidt, Carsten
DEUTSCHES ARZTEBLATT INTERNATIONAL, 2023, 120 (45): : 768 - 778
[24] Diet in Treatment of Inflammatory Bowel Diseases
Sasson, Alexa N.
Ananthakrishnan, Ashwin N.
Raman, Maitreyi
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (03) : 425 - +
[25] Food as Treatment of Inflammatory Bowel Diseases
Maldonado-Contreras, Ana
INFECTION AND IMMUNITY, 2022, 90 (05)
[26] Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing
D'Amico, Ferdinando
Fiorino, Gionata
Peyrin-Biroulet, Laurent
Danese, Silvio
IMMUNOTHERAPY, 2019, 11 (07) : 565 - 575
[27] Treatment of inflammatory bowel diseases: focusing on biologic agents and new therapies
Song, Hyo Yeop
Seo, Geom Seog
JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2021, 64 (09): : 605 - 613
[28] Extracellular Vesicles: A New Nano Tool for the Treatment of Inflammatory Bowel Diseases
Tandra, Nitin
Wu, Peipei
Hu, Xinyuan
Mao, Fei
Xu, Wenrong
Qian, Hui
CURRENT NANOSCIENCE, 2019, 15 (06) : 589 - 595
[29] New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming?
D'Amico, Ferdinando
Peyrin-Biroulet, Laurent
Danese, Silvio
Fiorino, Gionata
CURRENT OPINION IN PHARMACOLOGY, 2020, 55 : 141 - 150
[30] Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review
Radin, Massimo
Sciascia, Savino
Roccatello, Dario
Cuadrado, Maria Jose
BIODRUGS, 2017, 31 (01) : 37 - 49

← 1 2 3 4 5 →